NEALS CLINICAL RESEARCH STUDIES

As part of our mission to translate advances in ALS research into clinical trials for patients as rapidly as possible, NEALS performs high quality clinical trials of potentially therapeutic agents to treat ALS. The NEALS Consortium also supports other projects, such as studies related to natural history, biomarkers, and the effects of ancillary treatment on disease progression.

The clinical trials listed below are trials performed by NEALS members using NEALS infrastructure. Click on the title of a trial to learn more.

For more information on any trial listed below or other ALS trials please visit http://www.clinicaltrials.gov

 

Status

Clinical Research Study

Information Last Updated    

Currently Recruiting

A Multicenter Study for the Validation of ALS Biomarkers

The purpose of this study is to collect 600 blood samples from healthy subjects, and both blood and 210 cerebrospinal fluid (CSF) samples from people with amyotrophic lateral sclerosis (ALS), pure lower or upper motor neuron diseases, as well as other neurodegenerative diseases. Through comparison of these samples, the researchers hope to learn more about the underlying cause of ALS, as well as find unique biological markers, which could be used to diagnose ALS and monitor disease progression.

 07/08/2009

Currently Recruiting

Clinical Trial of Ceftriaxone in Subjects with ALS

The trial is a double-blind, placebo controlled, multi-stage study to determine the safety, tolerability, and efficacy of ceftriaxone treatment in 600 people with ALS.

 07/06/2009

 Currently Recruiting

The Pre-Familial ALS (pre-fALS) Study


Investigators at Emory have been pursuing the idea that it may be possible to delay or prevent the onset of disease in people who are risk for developing ALS. The pre-fALS study has been designed and is being implemented in an effort to identify risk factors that might be used to predict those at greatest risk and to characterize the earliest preclinical stages of the disease.

 04/03/2009

Currently Recruiting

Randomized, Placebo-Controlled Trial of Arimoclomol in SOD1
Positive Familial ALS Trial

 

A seamless adaptive-design phase II/III study in which participants will be evaluated twice at a study center (Emory or the MGH) and thereafter in participants’ homes by a NEALS coordinator.

 04/03/2009

 Currently Recruiting

 

ATLIS

We have developed a new device that accurately measures isometric strength called: Accurate Test of Limb Isometric Strength (ATLIS). This device was designed to be portable, quick, and easy to use, while generating accurate and reliable, interval level data.

 04/03/2009

Currently Recruiting

A Phase 1, Double-Blind, Placebo-Controlled, Dose-Escalation Study of the Safety, Tolerability, and Pharmacokinetics of ISIS 333611 Administered Intrathecally to Patients with Familial Amyotrophic Lateral Sclerosis Due to Superoxide Dismutase 1 Gene Mutations

This Phase I study will evaluate the safety, tolerability, and pharmacokinetics of a new investigational drug, antisense oligonucleotide ISIS 333611, also known as SOD1.

 

 

01/21/2010

 

Completed

A Multicenter, Double-Blind, Placebo-Controlled Study to Investigate the Safety and Efficacy of Lithium in combination with Riluzole in Volunteers with Amyotrophic Lateral Sclerosis (ALS) Protocol No. LALS-001

 

 

 09/23/2009


website solution provided by AQWebsites